Recurrent Severe Acute Kidney Injury From Immunotactoid Glomerulonephritis and Response to Rituximab

Edin Adilovic^{1

2}, Sonali Gupta^{1

2}, Fabricio Hernandez^{1

2}, Joseph Mattana^{1

2}, Aaron Dommu³

Affiliations

¹ Department of Medicine, St. Vincent's Medical Center, Bridgeport, CT.
² The Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT.
³ Nephrology Associates, Bridgeport, CT.

Edin Adilovic et al. Am J Ther. 2021 Jan-Feb.

. 2021 Jan-Feb;28(1):e162-e164.

doi: 10.1097/MJT.0000000000001018.

Edin Adilovic^{1

2}, Sonali Gupta^{1

2}, Fabricio Hernandez^{1

2}, Joseph Mattana^{1

2}, Aaron Dommu³

¹ Department of Medicine, St. Vincent's Medical Center, Bridgeport, CT.
² The Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT.
³ Nephrology Associates, Bridgeport, CT.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

1. Sathyan S, Khan FN, Ranga KV. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. Transpl Proc. 2009;41:3953–3955.
1. Hogan J, Restivo M, Canetta PA, et al. Rituximab treatment for fibrillary glomerulonephritis. Nephrol Dial Transpl. 2014;29:1925–1931.
1. Leibler C, Moktefi A, Matignon M, et al. Rituximab and fibrillary glomerulonephritis: interest of B cell reconstitution monitoring. J Clin Med. 2018;7:430.